March 18, 2020 / 8:45 AM / 11 days ago

BRIEF-Ergomed Announces Covid-19 Clinical Study

March 18 (Reuters) - Ergomed PLC:

* ERGOMED PLC - ERGOMED ANNOUNCES COVID-19 CLINICAL STUDY

* ERGOMED PLC - INITIATION OF A STUDY OF SILTUXIMAB, AN INTERLEUKIN (IL)-6 TARGETED MONOCLONAL ANTIBODY

* ERGOMED-EUSA PHARMA, PAPA GIOVANNI XXIII HOSPITAL, BERGAMO ANNOUNCE INITIATION OF OBSERVATIONAL CASE-CONTROL STUDY OF SILTUXIMAB IN COVID-19 PATIENTS

* ERGOMED PLC - STUDY IS SPONSORED BY PAPA GIOVANNI XXIII HOSPITAL IN BERGAMO, ITALY AND SUPPORTED BY EUSA PHARMA (EUSA) Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below